Besotifan treatment costs and medical insurance reimbursement policy

As a targeted drug, Belzutifan is mainly used to treat certain types of cancer, such as renal cell carcinoma (RCC) with VHL gene mutations. This drug reduces the growth and spread of tumor cells by inhibiting the activity of HIF-2α protein, and therefore has become one of the important drugs in the treatment of VHL mutation-related diseases. Besotivan has been on the market for a short time in China, and detailed information about its price and medical insurance reimbursement policy is not yet fully clear.

In Hong Kong, China, the price of besotivan is relatively high. The Hong Kong version of the original drug is sold for 40mg*90 tablets per box, which may reach hundreds of thousands of yuan, far beyond the ability of many patients to pay. Therefore, the cost of this drug has always been a focus of attention. In China, due to the short time that drugs have entered the market, patients' treatment costs and medical insurance coverage have not yet been fully disclosed. When choosing to purchase, consult with hospitals and drug manufacturers.

However, in addition to the original drug, some overseas countries also provide generic versions of bezutivan. Taking the Lao version of generic drugs as an example, each box of drugs with the same specifications sells for about more than 5,000 yuan. The price is relatively affordable, and the ingredients and effects of the drugs are basically the same as the original drugs. Although the price is cheap, patients still need to choose carefully to ensure the quality and reliability of medicines and avoid potential health risks caused by low prices.

As for medical insurance reimbursement, it is unclear whether Bezotivan has entered China's medical insurance system. Considering the high cost of treatment, if patients can be reimbursed through medical insurance, the treatment burden may be greatly reduced. However, the specific reimbursement policy still needs to be determined according to the relevant regulations of medical insurance in each region and the approval process of drugs in the country.

Overall, treatment costs with besetivan are higher, especially for the brand-name drug, but generics provide an economical option for some patients. Before drugs enter the medical insurance system and are included in the scope of reimbursement, patients still have to rely on purchasing drugs at their own expense. Choosing the appropriate purchasing channel is the most important issue at present.

Reference materials:https://www.welireg.com/